Mesoblast stem cell therapy meets goal of pediatric Graft vs Host study
February 21, 2018 at 18:00 PM EST
Feb 21 (Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian company announced on Wednesday.